Clinical Trial Update: MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial of MLN1117 in combination with docetaxel, paclitaxel, and other investigational anticancer agents in advanced/metastatic gastric/gastroesophageal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma
• Or Metastatic Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• MLN1117 (MLN1117)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Phase 1 | Status: TERMINATED | Results posted: 2019-09-20